je.st
news
Home
› Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer
Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer
2015-04-29 05:17:09| drugdiscoveryonline Home Page
Pfizer Inc. announced recently that XALKORI (crizotinib) received Breakthrough Therapy designation by the U.S
Tags: cell
treatment
cancer
patients
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||